ASAbdul Sattar Shaikh

Abdul Sattar Shaikh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdul Sattar Shaikh has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Closing the Gap in Neonatal Congenital Heart Disease Care: The Role of the NICVD Network

    by Nida Rafique, Aurangzeb Shaikh, Abdul Sattar Shaikh, Hussain Bux, Veena Kumari, Aliya Kemal Ahsan, Shakeel Memon

    Critical congenital heart disease (CCHD) is a major contributor to neonatal morbidity and mortality, particularly in low- and middle-income countries (LMICs), where delays in diagnosis and treatment can be fatal. In Pakistan, limited access to specialist services, referral delays and financial barriers complicate timely care. Role of the National Institute of Cardiovascular Diseases (NICVD) network: Improving neonatal CCHD outcomes requires a coordinated continuum of care, not cardiac surgery alone. Clinical assessment and pulse-oximetry screening should support early recognition and prompt echocardiographic evaluation. Neonates with suspected duct-dependent lesions require urgent stabilization, specialist consultation and safe transfer. The NICVD network could link screening, diagnosis, stabilization, neonatal transport, catheter-based or surgical treatment, intensive care and follow-up. Future priorities: Standardized referral and stabilization protocols, specialist neonatal transport, prostaglandin therapy when indicated, neonatal cardiac intensive care and systematic outcome audits are essential. Prospective neonatal-specific data are needed to evaluate implementation and outcomes. By connecting early detection with timely specialist intervention, an integrated NICVD network could help reduce avoidable deaths associated with neonatal CCHD in Pakistan.

  • Open Access

    Time, Transition, and Triumph: Redefining Early Detection Strategies for Neonatal Cardiac Lesions

    by Abdul Sattar Shaikh, Hussain Bux, Veena Kumari, Aliya Kemal Ahsan, Nida Rafique, Aurangzeb Shaikh, Shakeel Memon, Aiza Wahab

    Congenital heart disease (CHD) is a major contributor to neonatal morbidity and mortality, particularly in low- and middle-income countries. Importantly, newborns with critical congenital heart disease (CCHD) may appear clinically well immediately after birth. The absence of cyanosis, respiratory distress, or an audible murmur therefore cannot reliably exclude a serious cardiac lesion. Duct-dependent systemic or pulmonary circulation and transposition physiology may remain temporarily compensated until postnatal circulatory changes reveal the underlying defect. The transition from fetal to neonatal circulation offers a crucial opportunity for detection before clinical deterioration. Although prenatal ultrasonography and targeted fetal echocardiography can identify important structural anomalies, variable access, operator expertise, image quality, and referral systems leave some lesions undetected. Postnatal screening must consequently combine careful physical examination with pulse oximetry and prompt echocardiographic assessment when indicated. In Pakistan, shortages of trained personnel and equipment, inconsistent screening practices, limited specialist services, and socioeconomic barriers can delay recognition and referral. This editorial advocates a coordinated, feasible screening pathway that links antenatal assessment, standardized newborn examination, pulse oximetry, clinical escalation, echocardiographic confirmation, and timely referral. The objective is to recognize potentially life-threatening cardiac disease before discharge whenever possible, while maintaining vigilance for lesions that may escape initial screening.

  • Open Access

    Editorial Comment: Electrocardiography in Pediatric Myocarditis: An Established Tool with Renewed Clinical Significance

    by Muhammad Mohsin, Shazia Mohsin, Abdul Sattar Shaikh

    Pediatric myocarditis remains a formidable diagnostic challenge because of its heterogeneous clinical presentation, variable disease severity, and potential for rapid cardiovascular deterioration. Affected children may initially present with nonspecific manifestations, including fever, fatigue, gastrointestinal symptoms, respiratory complaints, dyspnea, or chest discomfort. However, some patients progress rapidly to ventricular dysfunction, cardiogenic shock, or life-threatening arrhythmias. Early recognition is therefore essential, particularly in resource-constrained healthcare settings where cardiac magnetic resonance imaging (CMR), endomyocardial biopsy, and specialized electrophysiological investigations may not be readily available [1-3]. Against this clinical background, the prospective study by Akbar and colleagues offers valuable insights into the electrocardiographic characteristics and arrhythmic complications of clinically suspected pediatric myocarditis in Pakistan [4]. By evaluating 106 children over a two-year period, the investigators highlight the continuing importance of the conventional 12-lead electrocardiogram (ECG) as an accessible, noninvasive, and clinically informative component of cardiovascular assessment. Although advanced cardiac imaging has substantially improved the characterization of myocardial inflammation, ECG remains indispensable for identifying electrical disturbances and supporting timely clinical decision-making [5,6]. A particularly noteworthy observation was the high prevalence of electrocardiographic abnormalities. Sinus tachycardia was documented in 96.2% of patients, while ST-T abnormalities and low-voltage QRS complexes were identified in 49.1% and 38.7%, respectively. Sustained arrhythmias occurred in 27 children (25.5%), with more than 80% of these events developing within the first 72 hours of hospitalization. These findings underscore the importance of early rhythm surveillance and suggest that the initial hospitalization period represents a critical window for detecting potentially serious electrical instability [4]. The predominance of tachyarrhythmias further emphasizes the heterogeneous electrophysiological manifestations of suspected myocarditis. Supraventricular tachycardia was the most frequently observed sustained arrhythmia, followed by ventricular tachycardia, while complete atrioventricular block and clinically significant bradyarrhythmias were also reported. This spectrum is broadly consistent with previous pediatric investigations demonstrating that myocardial inflammatory processes may be accompanied by both supraventricular and ventricular rhythm disturbances [7,8]. Nevertheless, an important diagnostic consideration concerns the potential overlap between primary myocarditis and tachycardia-induced cardiomyopathy. Sustained tachyarrhythmias may themselves produce ventricular dysfunction, heart failure, and elevations in cardiac biomarkers, thereby mimicking manifestations of acute myocardial inflammation. Consequently, some children classified as having clinically suspected myocarditis may instead have experienced tachycardia-mediated ventricular dysfunction. Without confirmatory imaging, histopathological evidence, or systematic assessment of ventricular recovery following rhythm control, this possibility cannot be fully excluded. Such diagnostic uncertainty is particularly relevant when arrhythmia represents both a presenting manifestation and an outcome of interest. Future investigations should therefore distinguish arrhythmias present at admission from those developing subsequently and, where feasible, assess changes in ventricular function after restoration of sinus rhythm. Perhaps the most clinically significant finding was the strong association between ST-T abnormalities and sustained arrhythmias. These abnormalities were present in 85.2% of children who experienced sustained arrhythmias, compared with 36.7% of those without such events. Following multivariable adjustment, ST-T abnormalities remained associated with sustained arrhythmia, yielding an adjusted odds ratio of 9.85. Previous pediatric studies have similarly indicated that repolarization disturbances may carry clinically relevant information regarding arrhythmic complications [8]. However, this association warrants cautious interpretation. First, ST-T abnormalities are not specific to myocarditis and may occur in other myocardial, metabolic, or systemic conditions. Second, because electrocardiographic abnormalities contributed to the eligibility criteria for clinically suspected myocarditis, their subsequent evaluation as predictors introduces the possibility of incorporation-related selection bias. This methodological issue may influence the magnitude and generalizability of the observed association. Moreover, ST-T abnormalities may reflect underlying myocardial injury or greater disease severity rather than functioning as independent causal determinants of arrhythmogenesis. The relatively small number of sustained arrhythmic events also limits the precision and stability of the multivariable estimates. With only 27 events, the potential for model overfitting requires consideration, particularly if several explanatory variables were included. Accordingly, the reported association should be interpreted as an exploratory risk marker rather than evidence of a validated predictive relationship. Larger, adequately powered, multicenter investigations with prespecified statistical models and external validation are necessary before ST-T abnormalities can be incorporated into a formal pediatric myocarditis risk-stratification algorithm. Another important contribution of the study is its emphasis on serial electrocardiographic assessment. A single ECG obtained at presentation may not adequately capture the evolving electrophysiological consequences of myocardial disease. The investigators employed ECG recordings at admission and at 12-hour intervals,...

  • Open Access

    Editorial Comment: Transcatheter Closure of Patent Ductus Arteriosus in Infants: Interpreting High Procedural Success and Its Implications for Pediatric Cardiology in Pakistan

    by Abdul Razzaq Mughal, Motia Javed, Abdul Sattar Shaikh

    The management of patent ductus arteriosus (PDA) has undergone considerable advancement over recent decades, reflecting improvements in diagnostic imaging, catheter-based interventions, device technology, and perioperative care. Contemporary clinical decision-making extends beyond identifying ductal patency to determining its hemodynamic significance, evaluating the anticipated benefits of intervention, and selecting the safest and most effective closure strategy. Transcatheter PDA closure has emerged as an important alternative to surgical ligation in appropriately selected patients, with expanding applications in infants of increasingly lower body weights [1–3]. Nevertheless, successful intervention requires careful consideration of ductal anatomy, patient characteristics, procedural expertise, and potential complications. The retrospective study by Riaz et al. [4], published in the current issue of the Pakistan Heart Journal, provides valuable evidence regarding the feasibility and early outcomes of transcatheter PDA closure in infants within a Pakistani tertiary-care setting. Over the study period, 247 infants underwent evaluation, of whom 239 proceeded to attempted transcatheter closure. Successful device implantation was achieved in 238 patients, corresponding to a procedural success rate of 99.6% among attempted interventions. Only one major complication, device embolization, was documented and successfully managed through percutaneous retrieval. Five additional patients experienced minor complications, while no procedure-related mortality or clinically significant left pulmonary artery or descending aortic obstruction was identified before discharge. These findings are encouraging and highlight the potential for favorable procedural outcomes when interventions are performed in experienced centers with appropriate patient selection and multidisciplinary support. The reported success rate compares favorably with published international experiences, although differences in patient characteristics and procedural complexity warrant careful interpretation. Backes et al. [5], analyzing data from the National Cardiovascular Data Registry IMPACT Registry, reported a procedural success rate of 94.3% among 747 infants weighing less than 6 kg. However, this population included substantially smaller and younger infants than those represented in the present study. Similarly, earlier multicenter investigations demonstrated the feasibility of transcatheter PDA closure in infants weighing 6 kg or less, while emphasizing the importance of patient selection and procedural expertise [6]. Consequently, the exceptionally high success rate reported by Riaz et al. should be interpreted in the context of the study population rather than as evidence of superior effectiveness across all infant age and weight categories. An important contribution of this study is its demonstration of individualized device selection according to ductal morphology and anatomical characteristics. Conventional PDA occluders were employed in most procedures, whereas ventricular septal defect occluders were utilized in selected patients with larger or atypical ductal configurations. Such procedural adaptability is particularly relevant in pediatric interventional cardiology, where anatomical variability can influence device stability, residual shunting, and the risk of obstruction involving adjacent vascular structures. Device selection should therefore incorporate ductal diameter, length, configuration, patient body weight, and the anatomical relationship between the ductus, descending aorta, and left pulmonary artery [7]. The findings reinforce the importance of anatomy-guided intervention rather than reliance on a uniform device strategy. The vascular access strategy adopted in this cohort also deserves attention. A venous-only approach was employed in 61.9% of procedures, suggesting the feasibility of minimizing arterial instrumentation in selected infants. Avoidance of femoral arterial access may reduce exposure to access-related vascular complications, which are particularly concerning in smaller patients because of limited vessel caliber. Previous investigations have demonstrated the feasibility and effectiveness of venous-only transcatheter PDA closure, although procedural suitability depends on ductal anatomy, imaging capabilities, device characteristics, and operator experience [8,9]. Accordingly, venous-only access should be considered an individualized procedural option rather than a universally preferable technique. Importantly, the present retrospective findings do not establish comparative superiority over conventional arteriovenous approaches. Despite the favorable procedural outcomes, the occurrence of device embolization highlights the need for continued vigilance regarding potentially serious complications. Although successfully managed through percutaneous retrieval in the present series, device embolization may necessitate urgent intervention and can result in substantial clinical consequences if not promptly recognized. The availability of appropriate retrieval equipment, immediate echocardiographic and fluoroscopic assessment, experienced interventional personnel, and surgical backup remains essential for safe procedural practice. International evidence similarly emphasizes that technical success must be evaluated alongside procedural complications and institutional preparedness [5,7]. An additional consideration concerns the generalizability of these findings. The study population had a mean age of 11.0 months and mean body weight of 7.8 kg, indicating that the findings predominantly reflect outcomes among relatively larger infants. They should not be extrapolated directly to premature neonates, extremely low-birth-weight infants, or patients with substantially different hemodynamic and anatomical characteristics. Although advances in transcatheter techniques have expanded treatment options for...

  • Open Access

    SGLT2 Inhibition in the Fontan Population: A New Dawn for the Single Ventricle

    by Aliya Kemal Ahsan, Makhdoom Bilawal, Syed Waseem Jamalvi, Abdul Sattar Sheikh, Sana Javed

    Addressing the Clinical Dilemma of Fontan Circulation: Few innovations in modern cardiac surgery have had as profound and transformative an impact on the management of congenital heart disease as the Fontan procedure. It has converted what was once a uniformly fatal form of single-ventricle heart disease into a chronic condition compatible with long-term survival [1,2]. However, for clinicians working at the interface of pediatric and adult congenital cardiology, Fontan completion does not represent the end of treatment—it marks the beginning of a lifelong physiological journey. This journey is increasingly characterized by Fontan failure, a multisystem syndrome driven by chronic venous congestion, reduced cardiac output, and progressive end-organ dysfunction [3,4]. Historically, the pharmacological management of Fontan failure has been challenging. For decades, clinicians have attempted to apply the traditional "four pillars" of heart failure therapy, developed for patients with biventricular circulation, to those with Fontan physiology. Unfortunately, these therapies have generally failed to produce meaningful improvements in mortality, exercise capacity, or quality of life [2]. Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers have demonstrated only limited clinical benefit because they do not address the unique hemodynamic characteristics of the Fontan circulation [3]. Physiological Challenges: The Fontan circulation is fundamentally different from normal cardiovascular physiology because it lacks a subpulmonary ventricle. Pulmonary blood flow is entirely passive and depends on elevated central venous pressure to drive blood through the pulmonary vascular bed [3]. Consequently, conventional heart failure therapies that reduce preload may inadvertently compromise pulmonary blood flow and systemic cardiac output. This unique physiology has created a substantial therapeutic gap for the growing population of adults with congenital heart disease, who continue to lack pharmacological therapies capable of improving systemic outcomes without destabilizing Fontan hemodynamics [3,4]. A New Therapeutic Horizon: SGLT2 Inhibitors: Sodium-glucose cotransporter-2 (SGLT2) inhibitors were originally developed as glucose-lowering agents for patients with type 2 diabetes mellitus. However, they have rapidly emerged as a cornerstone of therapy for patients with heart failure across the spectrum of left ventricular ejection fraction because of their cardiovascular and renal protective effects [5,6]. Their potential application in adults with congenital heart disease represents an exciting new frontier. A landmark multicenter study by Neijenhuis et al., published in the Journal of the American College of Cardiology in 2024, entitled "Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults with Congenital Heart Disease," provides some of the earliest and most comprehensive evidence regarding the safety and efficacy of these agents in this unique population [7]. The study evaluated 174 adults with congenital heart disease, including patients with complex univentricular physiology. Importantly, treatment with SGLT2 inhibitors was associated with a significant reduction in heart failure hospitalizations over a six-month follow-up period. Equally encouraging was the favorable safety profile, with minimal incidences of symptomatic hypotension or clinically significant renal dysfunction—complications that frequently limit the use of conventional heart failure therapies in Fontan patients [7]. Early Clinical Evidence in Adult Congenital Heart Disease: The multicenter cohort by Neijenhuis et al. may represent an important turning point in the management of adult congenital heart disease [7]. Among 174 adults, the majority receiving SGLT2 inhibitors for symptomatic heart failure, treatment was associated with an approximately threefold reduction in heart failure hospitalization during the six months following treatment initiation compared with the preceding six months (rate ratio 0.30; 95% CI 0.14–0.62) [7]. Mortality remained low (2.3%) and none of the reported deaths were attributed to SGLT2 inhibitor therapy [7]. These findings suggest that SGLT2 inhibitors function not merely as antidiabetic agents but as clinically meaningful modulators of cardiovascular physiology. For Fontan patients, whose circulation depends upon a delicate balance between central venous pressure, pulmonary blood flow, and systemic cardiac output, these observations are particularly relevant [7]. Changes in Ventricular Function: Additional evidence supporting SGLT2 inhibitor therapy has emerged from smaller observational studies focusing on systemic right ventricular and single-ventricle failure. In a cohort of ten patients with systemic right ventricular dysfunction treated with dapagliflozin, median NT-proBNP concentrations decreased substantially over six months (736.6 to 531.6 ng/L), while approximately half of the patients experienced improvement in New York Heart Association (NYHA) functional class [8]. Similarly, short-term imaging studies have demonstrated early improvements in ventricular performance. Significant enhancements in global longitudinal strain, tricuspid annular plane systolic excursion (TAPSE), and fractional area change have been reported within 50 days in patients with systemic right ventricular failure. In patients with single-ventricle physiology, improvements in end-systolic area, fractional area change, free-wall strain, and isovolumic acceleration have been observed within approximately 100 days of therapy, particularly among individuals with reduced ventricular systolic function [9,10]. Safety and Tolerability: Safety remains a critical consideration in patients with complex congenital heart disease. In the multicenter ACHD cohort, adverse events were reported in approximately 10% of patients, while only 6.9% discontinued treatment because of side effects [7]....

  • Open Access

    Natural Course and Clinical Outcomes of Small Perimembranous Ventricular Septal Defects in Children at a Tertiary Cardiac Center: A Prospective Cohort Study

    by Muhammad Athar Ahmed, Hussain Bux Korejo, Aurangzeb Shaikh, Veena Kumari, Shah Nawaz Sathio, Muhammad Asif Khan, Abdul Sattar Shaikh

    Objectives: This study aimed to evaluate the natural course, spontaneous closure rate, and occurrence of structural complications among children with isolated small perimembranous ventricular septal defects (PM-VSDs managed at a tertiary cardiac center in Karachi. Methodology: This prospective observational cohort study was conducted at the Department of Pediatric Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan, between November 2025 and May 2026. A small PM-VSD was defined echocardiographically as a ventricular septal defect measuring less than 50% of the aortic annulus diameter, demonstrating a peak Doppler pressure gradient ≥50 mmHg, with no evidence of pulmonary hypertension or left heart chamber enlargement. A total of 550 consecutive pediatric patients aged 2–15 years with isolated small PM-VSDs were enrolled and followed prospectively through serial clinical assessments and transthoracic echocardiography. The mean follow-up duration was 3.33 months (IQR: 1.8–5.2 months). Primary outcomes included spontaneous defect closure, persistence of the defect, development of structural complications, and requirement for intervention. Results: A total of 550 patients were included in the final analysis. Male patients constituted 64% of the study population, and the mean age at diagnosis was 5.69 ± 4.4 years. Incidental cardiac murmur was the most frequent presenting finding. Spontaneous closure occurred in 12.54% (n=69) of patients, whereas persistent PM-VSD was observed in 57.2% (n=315). Progressive complications requiring intervention developed in 22.54% (n=124), while 7.63% (n=42) were lost to follow-up. Structural complications included aortic valve prolapse with aortic regurgitation (48.72%), right ventricular outflow tract obstruction (13.63%), infective endocarditis (6.0%), and rhythm disturbances (1.63%). Although spontaneous closure was numerically more frequent among children diagnosed before five years of age than in older children (14.0% vs. 10.7%), the difference was not statistically significant (χ²=1.43, p=0.49). Conclusion: Small PM-VSDs demonstrated a heterogeneous clinical course characterized by relatively low spontaneous closure rates and a substantial burden of structural complications in this cohort. These findings emphasize the importance of regular long-term clinical and echocardiographic surveillance for early recognition of disease progression and timely intervention to prevent irreversible cardiac complications.

  • Open Access

    The Next Global Health Priority: Why Congenital Heart Disease Must Be Included in National Non-Communicable Disease Strategies

    by Abdul Sattar Shaikh

    Congenital heart disease (CHD) is the most common congenital anomaly worldwide, affecting approximately 1 in every 100 live births. Advances in prenatal diagnosis, neonatal care, cardiac surgery, catheter-based interventions, and lifelong follow-up have transformed CHD from a fatal childhood condition into a chronic disease spanning the entire lifespan. Despite these achievements, congenital heart disease remains largely overlooked in national and global non-communicable disease (NCD) strategies, which predominantly focus on cardiovascular diseases of adulthood, diabetes, chronic respiratory diseases, and cancer. This omission is particularly detrimental in low- and middle-income countries (LMICs), where delayed diagnosis, limited specialized services, financial barriers, and inadequate workforce capacity continue to contribute to preventable mortality and lifelong disability. As survival improves globally, the number of adults living with congenital heart disease now exceeds the pediatric population, creating an emerging public health challenge. Integrating congenital heart disease into national NCD frameworks would facilitate comprehensive planning for prevention, early detection, specialized treatment, workforce development, sustainable financing, registries, and lifelong care. This editorial highlights why congenital heart disease should be recognized as the next global health priority and outlines practical recommendations for policymakers. Editorial Congenital heart disease is no longer a rare pediatric condition but a major global health challenge [1,2]. Advances in medical care have transformed CHD into the largest population of survivors with lifelong congenital cardiovascular disease, creating new responsibilities for health systems [3-5]. For decades, global non-communicable disease (NCD) strategies have concentrated on four major disease groups—cardiovascular disease, diabetes mellitus, chronic respiratory diseases, and cancer [6]. These priorities have undoubtedly improved health outcomes worldwide. However, an important and growing population has remained largely invisible within national health agendas: individuals living with congenital heart disease (CHD). Congenital heart disease is the commonest congenital anomaly, affecting nearly 1.35 million newborns annually worldwide [1,2]. Improvements in fetal diagnosis, neonatal intensive care, cardiac surgery, interventional cardiology, and medical management have dramatically increased survival [3-5]. Today, more than 90% of children born with CHD in high-income countries survive into adulthood [3-5]. Consequently, congenital heart disease has evolved from a pediatric disorder into a lifelong chronic cardiovascular disease requiring continuous multidisciplinary care [3,5,7]. Yet, national NCD strategies rarely acknowledge this changing epidemiology. A Growing but Neglected Global Health Burden: Although rheumatic heart disease has received increasing recognition within global cardiovascular health initiatives, congenital heart disease has remained underrepresented despite its substantial burden [6,8]. Every year, hundreds of thousands of children die because they lack timely diagnosis or access to definitive treatment [2,9]. Many survivors experience chronic heart failure, pulmonary hypertension, arrhythmias, infective endocarditis, stroke, neurodevelopmental impairment, or repeated hospitalizations that significantly reduce quality of life [5,7]. The disparity is greatest in low- and middle-income countries (LMICs), where nearly 90% of children with congenital heart disease are born [2,9-11]. Unfortunately, specialized pediatric cardiac centers, trained congenital cardiologists, congenital cardiac surgeons, advanced imaging facilities, and pediatric intensive care units remain scarce across many regions. The result is an unacceptable gap between disease burden and healthcare capacity. Congenital Heart Disease Fits the Definition of a Chronic Non-Communicable Disease: The exclusion of congenital heart disease from NCD policies is increasingly difficult to justify. Modern congenital heart disease fulfills every characteristic of a chronic non-communicable disease [5-7]: Lifelong disease requiring continuous follow-up Recurrent need for specialist healthcare Substantial healthcare expenditure Progressive complications throughout life Impact on education, employment, pregnancy, and mental health Requirement for multidisciplinary coordinated care Many adults with repaired congenital heart disease require repeated interventions, electrophysiology procedures, heart failure management, pulmonary hypertension therapy, cardiac transplantation assessment, and lifelong surveillance. Their healthcare needs resemble those of patients with other chronic cardiovascular diseases already included within NCD frameworks. Why National NCD Strategies Matter? Inclusion within national NCD strategies extends beyond symbolic recognition. It determines health financing, workforce planning, service delivery, data collection, and political commitment. Recognition of congenital heart disease as a national NCD priority would encourage governments to establish: National congenital heart disease registries Newborn pulse oximetry screening programs Prenatal cardiac screening pathways Regional referral networks Dedicated pediatric and adult congenital heart disease centers Specialized workforce training Sustainable financing mechanisms Lifelong transition services from pediatric to adult care. Such policies are especially important for countries where specialized congenital cardiac services remain centralized, forcing families to travel long distances for diagnosis and treatment [6,12,13]. The Challenge in Low and Middle Income Countries: The challenges faced by LMICs differ substantially from those in high-income countries. Delayed diagnosis, malnutrition, pulmonary vascular disease, limited catheterization facilities, shortage of pediatric...

  • Open Access

    The Emerging Adult Congenital Heart Disease Crisis in Pakistan: From Surgical Triumph to Systems Failure

    by Aliya Kemal Ahsan, Makhdoom Bilawal, Syed Waseem Jamalvi, Abdul Sattar Shaikh

    Rheumatic heart disease (RHD) remains one of the leading causes of acquired heart disease among children and adolescents in low- and middle-income countries despite being largely preventable. Although remarkable advances have been achieved in modern cardiology, including transcatheter interventions and precision medicine, RHD continues to disproportionately affect socioeconomically disadvantaged populations. In Pakistan, overcrowding, inadequate access to primary healthcare, delayed treatment of streptococcal infections, and inconsistent availability of antibiotics contribute to the sustained burden of disease. RHD develops as an autoimmune consequence of inadequately treated group A streptococcal pharyngitis, leading to progressive valvular damage and long-term cardiovascular complications. Many affected children remain undiagnosed until advanced stages of disease, presenting with severe mitral valve involvement, heart failure, pulmonary hypertension, atrial fibrillation, and recurrent hospitalizations. At this stage, surgical intervention often becomes the only viable treatment option. However, valve replacement in children presents substantial clinical challenges, as mechanical prostheses require lifelong anticoagulation and regular monitoring, while bioprosthetic valves frequently undergo premature degeneration, necessitating repeated surgical procedures. These challenges are further exacerbated by limited access to specialized cardiovascular care and long-term follow-up services in resource-constrained settings. The persistence of RHD in Pakistan reflects systemic gaps in prevention and healthcare delivery rather than a lack of medical knowledge. Every child requiring complex valve surgery for rheumatic disease represents a missed opportunity for early diagnosis, effective treatment of streptococcal infections, and sustained secondary prophylaxis. Strengthening prevention programs, ensuring reliable access to penicillin, improving community awareness, and expanding early screening initiatives are essential to reducing the burden of this preventable disease and improving cardiovascular outcomes among vulnerable pediatric populations.

  • Open Access

    Immediate and Short-Term Outcomes of Balloon Dilatation for Native Coarctation of the Aorta in Neonates and Infants at a Tertiary Care Center

    by Sana Javed, Abdul Sattar Shaikh, Hussain Bux Korejo, Veena Kumari, Aliya Kemal Ahsan, Nida Rafique

    Objectives: To evaluate the immediate and short-term outcomes of balloon dilatation for native CoA in neonates and infants, compare age-group differences, assess procedure-related complications, and identify predictors of recoarctation and re-intervention. Methodology: This ambispective observational cohort study was conducted at the Pediatric Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi. Neonates (≤28 days) and infants (29 days–12 months) undergoing balloon dilatation for native CoA were included. Immediate procedural success was defined as post-dilatation transcoarctation gradient <20 mmHg without major complications. Patients were followed for six months. Comparative statistical analyses were performed between neonates and infants, and multivariable logistic regression was used to identify predictors of recoarctation. Results: A total of 100 patients were included (55 infants, 45 neonates). Balloon dilatation resulted in a significant reduction in median gradient from 40.50 mmHg (IQR: 33–47.75) to 16.00 mmHg (IQR: 5–24.75) (p < 0.001). Immediate procedural success was higher in infants compared to neonates (65% vs. 42.2%; p = 0.02). At 6-month follow-up, recoarctation occurred in 23.47% of patients and was significantly more common in neonates (41.9% vs. 9.1%; p < 0.0001). Multivariable analysis identified age at intervention as an independent predictor of recoarctation (OR = 0.175; 95% CI: 0.057–0.535; p = 0.002). Major complication rates were low (4%). Conclusion: Balloon dilatation provides significant immediate hemodynamic improvement with acceptable short-term safety in neonates and infants with native CoA. Infants demonstrate higher procedural success and lower recoarctation rates compared to neonates. Age at intervention independently predicts short-term durability, emphasizing the need for vigilant follow-up in neonatal patients.

  • Open Access

    Procedural and Short-Term Outcomes of Patent Ductus Arteriosus Stenting in Patients with Duct-Dependent Congenital Heart Disease

    by Salah Uddin Kakar, Abdul Sattar Shaikh, Muhammad Ayyaz, Hussain Bux Korejo, Ali Raza, Nida Rafique, Sanam Khan

    Objectives: To evaluate procedural success, early clinical outcomes, complications, stent patency, pulmonary artery growth, and progression to surgical intervention following PDA stenting in neonates and young infants with duct-dependent congenital heart disease. Methodology: This was an observational cohort study with retrospective data collection and prospective clinical follow-up. This was an observational cohort study with retrospective data collection and prospective clinical follow-up for up to 12 months. Thirty patients with duct-dependent congenital heart disease underwent percutaneous PDA stenting at a single tertiary pediatric cardiac center. Baseline demographic, diagnostic, and procedural data were obtained from institutional medical records, while follow-up outcomes were assessed prospectively for up to 12 months. Evaluated variables included procedural success, oxygen saturation, hemodynamic stability, complications, pulmonary artery growth, surgical progression, and survival. Results: Successful stent deployment was achieved in all 30 infants. Post-procedural systemic oxygen saturation improved to 75–90%, with all patients achieving oxygen saturation greater than 80%. Most infants achieved early hemodynamic stability and required short intensive care unit stays. No early procedural complications or re-interventions were observed. One late stent thrombosis occurred during follow-up. Adequate pulmonary artery growth was observed in the majority of infants with available imaging. At 12 months, most patients had progressed to definitive or palliative surgical intervention, and overall survival was high. Conclusion: PDA stenting appears to be a feasible and effective palliative strategy in selected neonates with duct-dependent congenital heart disease, demonstrating high procedural success, early clinical stabilization, and acceptable short-term outcomes. Larger multicenter studies are needed to further define its role relative to surgical palliation.